Systematic Evaluation of Antiviral Medication in Schizophrenia

Overview

The purpose of this study is to examine whether antiviral medication will help improve psychotic symptoms and cognition in individuals early in the course of schizophrenia or schizoaffective disorder who are exposed to herpes simplex virus, type 1 (HSV 1), a virus that causes commonly occurring and recurrent cold sores.

Full Title of Study: “A Randomized Double-blind Controlled Trial of Valacyclovir Add-on Treatment of HSV Positive Early Course Schizophrenia Patients”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Investigator)
  • Study Primary Completion Date: September 2016

Detailed Description

The main objective of the study is to evaluate the efficacy of add-on treatment of Valacyclovir (VAV), an antiviral medication, in the treatment of early course schizophrenia/schizoaffective disorder patients. Our main hypothesis is that the VAV add-on treatment will improve positive, negative and cognitive symptoms in herpes simplex virus (HSV) positive schizophrenia or schizoaffective disorder patients. We hypothesize that the grey matter reductions in specific brain regions (such as prefrontal regions) will improve in patients on VAV + antipsychotic compared to those on placebo + antipsychotic and the improvements in positive, negative and cognitive symptoms will be correlated with the grey matter changes.

Interventions

  • Drug: Valacyclovir
    • 1 g PO BID x 2 weeks after 2 weeks it goes up to 1.5 g PO BID x 16 weeks along with antipsychotic
  • Drug: Placebo
    • 2 pills twice a day x 2 weeks, after 2 weeks 3 pills twice a day x 16 weeks along with antipsychotic

Arms, Groups and Cohorts

  • Experimental: Valacyclovir
    • 1 gram pill taken twice a day for 2 weeks, after 2 weeks it increased to 1.5 gram pill taken twice a day for 16 weeks.
  • Placebo Comparator: Sugar pill
    • 2 placebo pills taken twice a day for 2 weeks, after 2 weeks 3 pills taken twice a day for 16 weeks.

Clinical Trial Outcome Measures

Primary Measures

  • PANSS Positive and Negative Syndrome Scale for Schizophrenia
    • Time Frame: Baseline, Weeks 2, 4, 6, 10, 14, 18
    • This is a structured measure of severity of psychopathology that includes both positive and negative symptoms. The range is a minimum score of 30 and the maximum is 210. The lower scores suggest milder severity of illness domains.
  • Cognitive Function Neuropsychological Battery (Gur Battery)
    • Time Frame: Baseline, Week 18
    • All results are given as the mean difference between an 18 week follow-up and the baseline battery administrations.This is a computerized test that measures both accuracy and response times. A range for response times is not available because of individual variabilities. Accuracy scores can vary for each test: Working memory accuracy range was 0-16. Verbal memory accuracy range was 0-20. For both, the higher the score the better. No cut offs are available

Secondary Measures

  • Changes in Grey Matter Deficit
    • Time Frame: Baseline, Week 18
    • Gray matter volume changes (in cc) were measured using structural MRI. Changes were reported as gray matter volume in cc. Note: Assessment of blood oxygenation level dependent (BOLD) changes using fMRI were erroneously included in the original study record.

Participating in This Clinical Trial

Inclusion Criteria

  • Both genders between the ages of 18-50 years – Schizophrenia or schizoaffective disorder as defined in DSM-IV – Duration of illness 10 years or less – On a stable dose of an antipsychotic medication for at least a month – Should score 4 or more on at least one of the subscales of PANSS – Positive for HSV1 – Written informed consent Exclusion Criteria:

  • Substance abuse in the last month/dependence 6 months prior to the study – History of, or current medical/neurological illnesses which affects CNS function e.g., epilepsy, head injury with prolonged loss of consciousness – Pregnancy – History of immune disorders, HIV infection or currently receiving immunosuppressants – Subjects on regular antiviral therapy – History of hypersensitivity to Valacyclovir – Mental retardation as defined in DSM-IV

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Konasale Prasad
  • Collaborator
    • Stanley Medical Research Institute
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Konasale Prasad, Assistant Professor – University of Pittsburgh
  • Overall Official(s)
    • Konasale Prasad, MD, Principal Investigator, Western Psychiatric Institute and Clinic
    • Vishwajit Nimgaonkar, MD, PhD, Principal Investigator, Western Psychiatric Institute and Clinic
    • Matcheri Keshavan, MD, Principal Investigator, Wayne State University
    • Rajaprabhakaran Rajarethinam, MD, Principal Investigator, Wayne State University

References

Prasad KM, Shirts BH, Yolken RH, Keshavan MS, Nimgaonkar VL. Brain morphological changes associated with exposure to HSV1 in first-episode schizophrenia. Mol Psychiatry. 2007 Jan;12(1):105-13, 1. doi: 10.1038/sj.mp.4001915. Epub 2006 Oct 10.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.